Aurobindo Pharma today said it has recieved approval from the Canadian health regulator to sell its pain relieving drug Cyclobenzaprine tablets in the country.
The company has received approval for its abbreviated new drug submission for Cyclobenzaprine tablets (10 mg) from the Health Canada, Aurobindo said in a statement.
The tablets are the generic equivalent of Apotex Inc's 'ApoCyclobenzaprine'. The drug is used to treat muscle spasm associated with acute musculo-skeletal conditions, it said.
With these approvals Aurobindo now has 12 products approved by Health Canada.
Shares of Aurobindo were at Rs 914.10 on the BSE in late afternoon trade, down 2.05 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app